The Anti - inflammatory effects of Inhaled Corticosteroids versus Anti-Leukotrienes on the Lymphocyte P- Glycoprotein ( PGP) Expresion in Asthmatic Children
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F09%3A00009517" target="_blank" >RIV/61989592:15110/09:00009517 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The Anti - inflammatory effects of Inhaled Corticosteroids versus Anti-Leukotrienes on the Lymphocyte P- Glycoprotein ( PGP) Expresion in Asthmatic Children
Popis výsledku v původním jazyce
BACKGROUND: Inhaled corticosteroids (ICS) are used in asthma therapy for their anti-inflammatory effects. P-glycoprotein (PGP) is a transmembrane efflux pump for many drugs, including corticosteroids. Expression of PGP is associated with therapy resistant disease. OBJECTIVE: The purpose of this study was to compare expression levels of PGP in blood lymphocytes of pediatric asthma patients either on ICS or on the leukotriene inhibitor montelukast medication. PATIENTS AND METHODS: The evaluation of lymphocyte PGP expression was performed on a sample of 99 children (66 boys and 33 girls) aged 2-18 (median 12) years with intermittent or persisting mild asthma, (as defined by GINY 2002). The asthmatic children were divided into 3 groups: (1) treated by ICSbudesonide 200-400 microg per day (n = 27) more than 1 year; (2) treated by oral montelukast 4 or 5 mg at an age-based dose (n = 16); and (3) treated by inhaled corticosteroids and montelukast (n = 45). Reference PGP values were obtained
Název v anglickém jazyce
The Anti - inflammatory effects of Inhaled Corticosteroids versus Anti-Leukotrienes on the Lymphocyte P- Glycoprotein ( PGP) Expresion in Asthmatic Children
Popis výsledku anglicky
BACKGROUND: Inhaled corticosteroids (ICS) are used in asthma therapy for their anti-inflammatory effects. P-glycoprotein (PGP) is a transmembrane efflux pump for many drugs, including corticosteroids. Expression of PGP is associated with therapy resistant disease. OBJECTIVE: The purpose of this study was to compare expression levels of PGP in blood lymphocytes of pediatric asthma patients either on ICS or on the leukotriene inhibitor montelukast medication. PATIENTS AND METHODS: The evaluation of lymphocyte PGP expression was performed on a sample of 99 children (66 boys and 33 girls) aged 2-18 (median 12) years with intermittent or persisting mild asthma, (as defined by GINY 2002). The asthmatic children were divided into 3 groups: (1) treated by ICSbudesonide 200-400 microg per day (n = 27) more than 1 year; (2) treated by oral montelukast 4 or 5 mg at an age-based dose (n = 16); and (3) treated by inhaled corticosteroids and montelukast (n = 45). Reference PGP values were obtained
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NR8954" target="_blank" >NR8954: Stanovení polymorfismu genů pro P-glykoprotein jako produktu MDR1 génu (MDR1/Pgp) a MRP a expresi PgP, MRP1 a LRP na lymfocytech u pacientů s asthma bronchiale, Crohnovou nemocí a ulcerozní kolitidou.</a><br>
Návaznosti
Z - Vyzkumny zamer (s odkazem do CEZ)
Ostatní
Rok uplatnění
2009
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Asthma
ISSN
0277-0903
e-ISSN
—
Svazek periodika
46
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
5
Strana od-do
—
Kód UT WoS článku
—
EID výsledku v databázi Scopus
—